A Phase I, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 × CD3 dual-affinity re-targeting (DART®) protein in patients with relapsed/refractory metastatic colorectal carcinoma

Open Label ◽

Dose Escalation Study ◽

A phase 1, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 x CD3 DART molecule, in patients with relapsed/refractory metastatic colorectal carcinoma.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps3628 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS3628-TPS3628 ◽

Cited By ~ 2

Author(s):

John D. Powderly ◽

Herbert Hurwitz ◽

David P. Ryan ◽

Daniel A. Laheru ◽

Naimish B. Pandya ◽

...

Keyword(s):

Colorectal Carcinoma ◽

Dose Escalation ◽

Phase 1 ◽

Open Label ◽

Dose Escalation Study ◽

Abstract 1752: A phase I/IIa, first time in human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency

10.1158/1538-7445.am2012-1752 ◽

2012 ◽

Cited By ~ 4

Author(s):

Samuel C. Blackman ◽

Shelby D. Gainer ◽

Benjamin B. Suttle ◽

Konstantine W. Skordos ◽

Joel D. Greshock ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Dose Escalation ◽

Advanced Solid Tumors ◽

Open Label ◽

Dose Escalation Study ◽

Label Dose ◽

First Time

A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status

Cancer Medicine ◽

10.1002/cam4.1140 ◽

2017 ◽

Vol 6 (8) ◽

pp. 1904-1914 ◽

Cited By ~ 11

Author(s):

Benjamin Izar ◽

William Sharfman ◽

F. Stephen Hodi ◽

Donald Lawrence ◽

Keith T. Flaherty ◽

...

Keyword(s):

Phase I ◽

Metastatic Melanoma ◽

Dose Escalation ◽

Braf Mutation ◽

Locally Advanced ◽

Open Label ◽

Dose Escalation Study ◽

Mutation Status ◽

Phase I, Open-Label, Dose-Escalating Study of a Genetically Engineered Herpes Simplex Virus, NV1020, in Subjects with Metastatic Colorectal Carcinoma to the Liver

Human Gene Therapy ◽

10.1089/hum.2006.17.1214 ◽

2006 ◽

Vol 17 (12) ◽

pp. 1214-1224 ◽

Cited By ~ 112

Author(s):

Nancy Kemeny ◽

Karen Brown ◽

Anne Covey ◽

Teresa Kim ◽

Amit Bhargava ◽

...

Keyword(s):

Herpes Simplex Virus ◽

Herpes Simplex ◽

Colorectal Carcinoma ◽

Phase I ◽

Genetically Engineered ◽

Open Label ◽

Label Dose ◽

Simplex Virus ◽

Dose Escalating

Phase I, Open-Label, Dose-Escalating Study of a Genetically Engineered Herpes Simplex Virus, NV1020, in Subjects with Metastatic Colorectal Carcinoma to the Liver

Human Gene Therapy ◽

10.1089/hum.2006.17.ft-262 ◽

2006 ◽

Vol 0 (0) ◽

pp. 061115103131001

Author(s):

Nancy Kemeny ◽

Karen Brown ◽

Anne Covey ◽

Teresa Kim ◽

Amit Bhargava ◽

...

Keyword(s):

Herpes Simplex Virus ◽

Herpes Simplex ◽

Colorectal Carcinoma ◽

Phase I ◽

Genetically Engineered ◽

Open Label ◽

Label Dose ◽

Simplex Virus ◽

Dose Escalating

Combination of CpG7909 and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL): A phase I, open label dose-escalation study of safety and tolerability

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.6594 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 6594-6594

Author(s):

G. J. Weiner ◽

B. K. Link ◽

J. Leonard ◽

C. Emmanouilides ◽

G. Albert ◽

...

Keyword(s):

Phase I ◽

B Cell ◽

Dose Escalation ◽

Hodgkin’S Lymphoma ◽

Hodgkin's Lymphoma ◽

Open Label ◽

Dose Escalation Study ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma ◽

Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.3033 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 3033-3033 ◽

Cited By ~ 19

Author(s):

A. L. Ho ◽

J. C. Bendell ◽

J. M. Cleary ◽

G. K. Schwartz ◽

H. A. Burris ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Dose Escalation ◽

Advanced Solid Tumors ◽

Open Label ◽

Dose Escalation Study ◽

Abstract CT038: A phase I, open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of GSK3326595 in subjects with solid tumors and non-Hodgkin's lymphoma

10.1158/1538-7445.am2017-ct038 ◽

2017 ◽

Cited By ~ 2

Author(s):

Drew Rasco ◽

Anthony Tolcher ◽

Lillian L. Siu ◽

Kimberley Heinhuis ◽

Sophie Postel-Vinay ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Dose Escalation ◽

Hodgkin’S Lymphoma ◽

Hodgkin's Lymphoma ◽

Clinical Activity ◽

Open Label ◽

Dose Escalation Study ◽

Non Hodgkin's Lymphoma ◽

A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

BMC Cancer ◽

10.1186/s12885-017-3641-6 ◽

2017 ◽

Vol 17 (1) ◽

Cited By ~ 8

Author(s):

Kerry Lynn Reynolds ◽

Philippe L. Bedard ◽

Se-Hoon Lee ◽

Chia-Chi Lin ◽

Josep Tabernero ◽

...

Keyword(s):

Gastric Cancer ◽

Monoclonal Antibody ◽

Squamous Cell Carcinoma ◽

Phase I ◽

Dose Escalation ◽

Advanced Squamous Cell Carcinoma ◽

Open Label ◽

Dose Escalation Study ◽

Carcinoma Of The Esophagus ◽

Phase I, open-label, dose-escalation study of SNX-5422 plus everolimus in neuroendocrine tumors (NETs)

Annals of Oncology ◽

10.1093/annonc/mdw369.08 ◽

2016 ◽

Vol 27 ◽

pp. vi138

Author(s):

M.E. Gutierrez ◽

G. Giaccone ◽

S.V. Liu ◽

A. Rajan ◽

U. Guha ◽

...

Keyword(s):

Phase I ◽

Neuroendocrine Tumors ◽

Dose Escalation ◽

Open Label ◽

Dose Escalation Study ◽